סבלמר תרו 2.4 ג' - Sevelamer taro 2.4 g
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia | |||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||||||||||
| צ×רת ××ª× | פ××× - PER OS | |||||||||||||
| צ×רת ××× ×× | ×××§× ×××× ×ª תר×××£, POWDER FOR SUSPENSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | For the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ⥠1.78 mmol/l. Should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease. | |||||||||||||
| ||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר××¤× | |||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ס×××ר ×ª×¨× 2.4 ×' ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | SYNTHON HISPANIA S.L., SPAIN |
| ×©× ××¢× ×ר×ש×× | TARO INTERNATIONAL LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 3/2018. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | {{{ת×ר×× ×¢××××}}} |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־23 בפברואר 2024 ב־15:18